Home > Analytics > SUN PHARMA ADVANCED RESEARCH COMPANY

SUN PHARMA ADVANCED RESEARCH COMPANY
Intrinsic Value | Fundamental Analysis

BOM : 532872     NSE : SPARC    
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Average [Stock is fairly valued]
Debt : Low
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Downward
Pledged Shares : None or < 25%
Sep 28,2022
Price(EOD): ₹ 200.90
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Miscellaneous
MCap: ₹ 5,462.47 Cr
Value of ₹ 1 Lac invested in SUN PHARMA ADVANCED RESEARCH COMPANY
on Sep 28,2017 (price: ₹ 371.40)

₹ 1 L

₹ 0.54 L

1W : -9.9% 1M : -12.4% 1Y : -30.5%
COMMUNITY POLL
for SUN PHARMA ADVANCED RESEARCH COMPANY
Please provide your vote to see the results
Industry Peers & Returns1W1M1Y
SUN PHARMA ADVANCED RESEARCH COMPANY -9.9% -12.4% -30.5%
SYNGENE INTERNATIONAL -3% -9.4% -14.5%
QUESS CORP -3.3% 9.6% -31.9%
TEAMLEASE SERVICES -4.3% -9.5% -30.1%
SECURITY AND INTELLIGENCE SERVICES INDIA -0.8% -7.6% -11.8%
JUST DIAL -5.3% -8.6% -44.6%
DELTA CORP -7.5% -6.5% -17.2%
HEALTHCARE GLOBAL ENTERPRISES -5.5% -0.1% 11.7%
VA TECH WABAG -11.9% 1.7% -23.7%

FUNDAMENTAL ANALYSIS OF SUN PHARMA ADVANCED RESEARCH COMPANY

 
Fundamentals Score
[ Q(TTM): Jun2022, Y: Mar2022
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]


VALUATION OF SUN PHARMA ADVANCED RESEARCH COMPANY

 
Valuation Score
[As on : Sep 28,2022 ]

Ratio Standalone
P/E
P/B
P/S
-24.34
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs -224.38 Cr
[Latest Qtr - Jun2022 - Standalone Results ]

-26.9
P/B Calculated based on Book Value of Rs -203.03 Cr
[Latest Year - Mar2022 - Standalone Results ]

38
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Jun2022 - Standalone Results ]

Financial Ratios →

Insights 💡 There are potential 17% undervalued companies ! Discover More →

FAIR VALUE OF SUN PHARMA ADVANCED RESEARCH COMPANY

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
NA
-10%
-10%

Insights 💡 You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF SUN PHARMA ADVANCED RESEARCH COMPANY



SUN PHARMA ADVANCED RESEARCH COMPANY vs SENSEX


Insights 💡 You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF SUN PHARMA ADVANCED RESEARCH COMPANY

Year Debt/Equity ratio
Standalone Consolidated
2022
2021
2020
Avg_3yrs
-0.37
-1.37
-3.59
-1.78
-
-
-
-
[Last Annual Data : Mar2022]
Financial Ratios →

PLEDGED PROMOTER SHARES OF SUN PHARMA ADVANCED RESEARCH COMPANY

Pledged Promoter Shares
2.18 %
As on : Jun2022

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF SUN PHARMA ADVANCED RESEARCH COMPANY

Standalone Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
12.76%
-17.52%
-15.9%
-15.9%
29.42%
-44.09%
-34.19%
-34.19%
QtrlyTrend
-4
Latest Qtr: Jun2022
Quarterly Result Analysis →


SUN PHARMA ADVANCED RESEARCH COMPANY related INDICES

BSE Indices1W1M1Y
S&P BSE HEALTHCARE -1% 0.6% -13.9%
S&P BSE 250 SMALLCAP -4.3% -2.1% -2.4%
S&P BSE SMALL CAP -4.7% -1.9% -0.9%
S&P BSE 400 MIDSMALLCAP -4.8% -2.4% -2%
S&P BSE 500 -4.8% -3.5% -3.7%
NSE Indices1W1M1Y
NIFTY SMALLCAP250 -4.6% -2.4% -3.3%
NIFTY500 MULTICAP 50:25:25 -4.8% -3.1% -2.9%
NIFTY MID SMALL400 -4.8% -2.5% -0.6%
NIFTY 500 -4.8% -3.5% -3.9%
NIFTY FREE SMALL 100 -5.1% -3.8% -14.7%

You may also like the below Video Courses


FAQ about SUN PHARMA ADVANCED RESEARCH COMPANY


Is SUN PHARMA ADVANCED RESEARCH COMPANY good for long term investment?

As on Sep 28,2022, the Fundamentals of SUN PHARMA ADVANCED RESEARCH COMPANY look Poor and hence it may not be good for long term investment ! See Financial Performance of SUN PHARMA ADVANCED RESEARCH COMPANY . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is SUN PHARMA ADVANCED RESEARCH COMPANY UnderValued or OverValued?

As on Sep 28,2022, SUN PHARMA ADVANCED RESEARCH COMPANY is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!

What is the Intrinsic Value of SUN PHARMA ADVANCED RESEARCH COMPANY ?

As on Sep 28,2022, the Intrinsic Value of SUN PHARMA ADVANCED RESEARCH COMPANY is Rs. 223.05 estimated based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. -1,083.87
Fair Value [Median EV / Sales Model] : Rs. 222.72
Fair Value [Median Price / Sales Model] : Rs. 223.38
Estimated Median Fair Value of SUN PHARMA ADVANCED RESEARCH COMPANY : Rs. 223.05

The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.

Is SUN PHARMA ADVANCED RESEARCH COMPANY trading at a Premium or Discount?

As on Sep 28,2022, SUN PHARMA ADVANCED RESEARCH COMPANY is trading at a Discount of -10% based on the estimates of Median Intrinsic Value!

SEBI Research Analyst
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].